KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Non-Current Receivables (2019 - 2025)

Royalty Pharma's Non-Current Receivables history spans 7 years, with the latest figure at $16.2 billion for Q4 2025.

  • For Q4 2025, Non-Current Receivables rose 7.15% year-over-year to $16.2 billion; the TTM value through Dec 2025 reached $16.2 billion, up 7.15%, while the annual FY2025 figure was $16.2 billion, 7.15% up from the prior year.
  • Non-Current Receivables for Q4 2025 was $16.2 billion at Royalty Pharma, up from $15.8 billion in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $16.2 billion in Q4 2025 and bottomed at $12.6 billion in Q1 2021.
  • The 5-year median for Non-Current Receivables is $13.8 billion (2021), against an average of $14.1 billion.
  • The largest annual shift saw Non-Current Receivables increased 17.49% in 2021 before it fell 7.4% in 2023.
  • A 5-year view of Non-Current Receivables shows it stood at $13.7 billion in 2021, then dropped by 1.64% to $13.5 billion in 2022, then grew by 4.41% to $14.1 billion in 2023, then rose by 7.37% to $15.1 billion in 2024, then rose by 7.15% to $16.2 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Non-Current Receivables are $16.2 billion (Q4 2025), $15.8 billion (Q3 2025), and $15.1 billion (Q2 2025).